Locoregional Therapy for Hepatic Neuroendocrine Metastases

Abstract

Neuroendocrine tumors are a heterogeneous group of malignancies with diverse biological and clinical behavior. Locoregional treatments available for the initial and temporal management of neuroendocrine tumors involving the liver include transarterial embolization, transarterial chemoembolization, selective internal radiotherapy, and ablative techniques. These therapies are best employed as part of a multidisciplinary management team focusing on appropriate histopathology, timing, and individuality of each intervention.

Keywords

hepatic - locoregional - neuroendocrine

• References

• 1 Cho MY, Kim JM, Sohn JH. , et al; Gastrointestinal Pathology Study Group of Korean Society of Pathologists. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 2012; 44 (03) 157-165
• 2 Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39 (06) 707-712
• 3 Klöppel G, Couvelard A, Perren A. , et al; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90 (02) 162-166
• 4 Norheim I, Oberg K, Theodorsson-Norheim E. , et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206 (02) 115-125
• 5 Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013; 24 (12) 3040-3044
• 6 Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol 2009; 100 (08) 635-638
• 7 Yao JC, Hassan M, Phan A. , et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
• 8 Hauso O, Gustafsson BI, Kidd M. , et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113 (10) 2655-2664
• 9 Öberg K. Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10 (Suppl. 02) S3-S8
• 10 Godwin II JD. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975; 36 (02) 560-569
• 11 McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81 (07) 1007-1009
• 12 Zeitels J, Naunheim K, Kaplan EL, Straus II F. Carcinoid tumors: a 37-year experience. Arch Surg 1982; 117 (05) 732-737
• 13 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97 (04) 934-959
• 14 Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumours. Berlin, Heidelberg: Springer Science & Business Media; 2012
• 15 Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol 2014; 25 (02) 186-192
• 16 Pavel M, Baudin E, Couvelard A. , et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95 (02) 157-176
• 17 Veenendaal LM, Borel Rinkes IH, Lips CJ, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 2006; 4 (01) 35
• 18 Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 1999; 11 (01) 38-41
• 19 Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006; 17 (08) 1235-1249 , quiz 1250
• 20 Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin N-EA. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72 (03) 517-528
• 21 Richard R, Warner P, Kang Kim M. Carcinoid and related neuroendocrine tumors. In: Geschwind J-FH, Soulen MC. , eds. Interventional Oncology: Principles and Practice. New York, NY: Cambridge University Press; 2008: 290-300
• 22 Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180 (05) 1379-1384
• 23 Ho AS, Picus J, Darcy MD. , et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188 (05) 1201-1207
• 24 Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Contr 2006; 13 (01) 72-78
• 25 Sofocleous CT, Petre EN, Gonen M. , et al. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol 2014; 25 (01) 22-30 , quiz 31
• 26 Bodei L, Kidd M, Paganelli G. , et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015; 42 (01) 5-19
• 27 Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 2010; 14 (04) 347-351
• 28 Pitt SC, Knuth J, Keily JM. , et al. Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg 2008; 12 (11) 1951-1960
• 29 Gupta S, Johnson MM, Murthy R. , et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
• 30 Fiore F, Del Prete M, Franco R. , et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 2014; 47 (01) 177-182
• 31 Eriksson BK, Larsson EG, Skogseid BM, Löfberg A-M, Lörelius L-E, Öberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83 (11) 2293-2301
• 32 Kennedy A, Nag S, Salem R. , et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68 (01) 13-23
• 33 Dawson LA, McGinn CJ, Normolle D. , et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18 (11) 2210-2218
• 34 Salem R, Lewandowski RJ, Sato KT. , et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007; 10 (01) 12-29
• 35 Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 2010; 251 (05) 910-916
• 36 Paprottka PM, Hoffmann RT, Haug A. , et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 2012; 35 (02) 334-342
• 37 Kennedy AS, Dezarn WA, McNeillie P. , et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31 (03) 271-279
• 38 Murthy R, Kamat P, Nunez R. , et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 2008; 19 (01) 145-151
• 39 van Hazel GA, Heinemann V, Sharma NK. , et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15) 1723-1731
• 40 Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J 2010; 16 (02) 111-117
• 41 Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997; 122 (06) 1040-1047 , discussion 1047–1048
• 42 Giovannini M, Seitz JF. Ultrasound-guided percutaneous alcohol injection of small liver metastases. Results in 40 patients. Cancer 1994; 73 (02) 294-297
• 43 Livraghi T, Vettori C, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 1991; 179 (03) 709-712
• 44 Giovannini M. Percutaneous alcohol ablation for liver metastasis. Semin Oncol 2002; 29 (02) 192-195
• 45 Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 1998; 14 (02) 175-183
• 46 de Baere T, Deschamps F, Tselikas L. , et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 2015; 172 (04) R151-R166
• 47 Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26 (08) 985-990
• 48 Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142 (01) 10-19
• 49 Lorentzen T. A cooled needle electrode for radiofrequency tissue ablation: thermodynamic aspects of improved performance compared with conventional needle design. Acad Radiol 1996; 3 (07) 556-563
• 50 de Baere T, Elias D, Dromain C. , et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175 (06) 1619-1625
• 51 Solbiati L, Livraghi T, Goldberg SN. , et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221 (01) 159-166
• 52 Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30 (04) 435-441
• 53 Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010; 148 (06) 1288-1293 , discussion 1293
• 54 Mohan H, Nicholson P, Winter DC. , et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 2015; 26 (07) 935-942.e1
• 55 Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee Jr FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005; 236 (01) 132-139
• 56 Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010; 17 (01) 171-178
• 57 Walker K, Lindeque B. The application of cryoprobe therapy in orthopedic oncology. Orthopedics 2014; 37 (08) 536-540
• 58 Liu YY, Chiang PH, Chuang YC, Lee WC, Cheng YT, Wang HJ. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. Ann Surg Oncol 2015; 22 (05) 1612-1617
• 59 Yu H, Burke CT. Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors. Semin Intervent Radiol 2014; 31 (02) 129-137
• 60 Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int 2005; 95 (09) 1187-1191
• 61 Scheffer HJ, Nielsen K, de Jong MC. , et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 2014; 25 (07) 997-1011 , quiz 1011 quiz
• 62 Thomson KR, Cheung W, Ellis SJ. , et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22 (05) 611-621
• 63 Kingham TP, Karkar AM, D'Angelica MI. , et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215 (03) 379-387
• 64 Ebara M, Okabe S, Kita K. , et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43 (03) 458-464
• 65 Atwell TD, Charboneau JW, Que FG. , et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005; 28 (04) 409-421
• 66 Lahat E, Eshkenazy R, Zendel A. , et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr 2014; 3 (05) 317-323
• 67 Adam R, Hagopian EJ, Linhares M. , et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002; 137 (12) 1332-1339 , discussion 1340
• 68 Pearson AS, Izzo F, Fleming RY. , et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999; 178 (06) 592-599